ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial. - Soo RA; Dafni U; Han JY; Cho BC; Nadal E; Yeo CM; Carcereny E; de Castro J; Sala MA; Coate L; Provencio M; Britschgi C; et al. (Clinical Cancer Research, 2024)